S1K Stock Overview
A knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Predictive Oncology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.00 |
| 52 Week High | US$11.66 |
| 52 Week Low | US$4.00 |
| Beta | 1.49 |
| 11 Month Change | 0% |
| 3 Month Change | -17.36% |
| 1 Year Change | -51.87% |
| 33 Year Change | -85.82% |
| 5 Year Change | n/a |
| Change since IPO | -97.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| S1K | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.8% |
| 1Y | -51.9% | -5.0% | 9.1% |
Return vs Industry: S1K underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: S1K underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| S1K volatility | |
|---|---|
| S1K Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S1K's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine S1K's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 33 | Raymond Vennare | www.predictive-oncology.com |
Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.
Predictive Oncology Inc. Fundamentals Summary
| S1K fundamental statistics | |
|---|---|
| Market cap | €22.57m |
| Earnings (TTM) | -€23.03m |
| Revenue (TTM) | €1.28m |
17.7x
P/S Ratio-1.0x
P/E RatioIs S1K overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S1K income statement (TTM) | |
|---|---|
| Revenue | US$1.43m |
| Cost of Revenue | US$515.80k |
| Gross Profit | US$914.98k |
| Other Expenses | US$26.70m |
| Earnings | -US$25.79m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.44 |
| Gross Margin | 63.95% |
| Net Profit Margin | -1,802.42% |
| Debt/Equity Ratio | 0% |
How did S1K perform over the long term?
See historical performance and comparison